Your session is about to expire
← Back to Search
Vaccine
Adjuvanted vs Traditional Vaccines for Hepatitis B
Phase 4
Recruiting
Led By Ramin Herati, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
At least 18 years of age
Be older than 18 years old
Must not have
Known clinically significant anemia or contraindication to phlebotomy; i.e., anti-coagulation therapy or clinically significant thrombocytopenia
Known chronic HBV infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 1 post-final dose
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial will compare the traditional hepatitis B vaccine, which can cause nonresponses in some patients, to the CpG-adjuvanted HBV vaccine, which has far fewer rates of nonresponses.
Who is the study for?
This trial is for adults who can consent to participate and are generally healthy. It's not for those with chronic Hepatitis B, pregnant individuals, people with significant anemia or blood clotting issues, anyone on immune-suppressing drugs recently, or if the investigator thinks it's unsafe for them.
What is being tested?
The study compares two types of hepatitis B vaccines: the traditional one and a new CpG-adjuvanted vaccine designed to improve immune response. The goal is to understand why some people don't respond well to the current vaccine.
What are the potential side effects?
While specific side effects aren't listed here, typical reactions may include soreness at injection site, mild fever, fatigue or allergic responses. The adjuvant in the new vaccine could potentially cause different or more pronounced reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a serious form of anemia or a condition that makes drawing blood unsafe.
Select...
I have a long-term hepatitis B infection.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ month 1 post-final dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 1 post-final dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of Participants with Weak Vaccine Response
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: CpG-adjuvanted HBV VaccineExperimental Treatment1 Intervention
Group II: Traditional HBV VaccineActive Control1 Intervention
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,410 Previous Clinical Trials
855,406 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,323 Previous Clinical Trials
5,364,974 Total Patients Enrolled
1 Trials studying Vaccine Reaction
10 Patients Enrolled for Vaccine Reaction
Ramin Herati, MDPrincipal InvestigatorNYU Langone Health
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't taken immune-suppressing drugs in the last 30 days.I have a serious form of anemia or a condition that makes drawing blood unsafe.I have a long-term hepatitis B infection.I am 18 years old or older.I am HIV positive and have had a poor response to the HBV vaccine.
Research Study Groups:
This trial has the following groups:- Group 1: CpG-adjuvanted HBV Vaccine
- Group 2: Traditional HBV Vaccine
Awards:
This trial has 3 awards, including:- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger